Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,007 stopped studies mapped to B-Cell Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,007 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00871546 | SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia… | Phase 2 | terminated | Mar 30, 2009 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT01889420 | Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With… | Phase 1 | terminated | Jun 28, 2013 | New Mexico Cancer Research Alliance | Low accrual | Enrollment / accrual |
| NCT01908387 | Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms | Phase 1 | terminated | Jul 25, 2013 | Celgene Corporation | Due to Slow Accrual study was terminated. | Enrollment / accrual |
| NCT01497275 | Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma | Phase 2 | terminated | Dec 22, 2011 | Duke University | Low accrual due to the approval of new drugs for use in Mantle cell lymphoma. | Enrollment / accrual |
| NCT00431340 | A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed,… | Phase 2 | terminated | Feb 5, 2007 | Valerio Therapeutics | Terminated due to dose limiting toxicity | Safety / toxicity |
| NCT00522392 | Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With… | Phase 3 | terminated | Aug 29, 2007 | National Cancer Institute (NCI) | Slow accrual | Enrollment / accrual |
| NCT00963495 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients… | Phase 1 | terminated | Aug 21, 2009 | University Health Network, Toronto | not stated | Not stated |
| NCT01846429 | Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain | Phase 1 | terminated | May 3, 2013 | H. Lee Moffitt Cancer Center and Research Institute | Drugs unavailable. Study did not progress to Phase 2. | Other (stated, no rule matched) |
| NCT01769911 | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With… | N/A | withdrawn | Jan 17, 2013 | Fred Hutchinson Cancer Center | not stated | Not stated |
| NCT00395967 | AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients… | Phase 2 | terminated | Nov 6, 2006 | Genzyme, a Sanofi Company | Enrollment terminated in 2005 to focus on Phase 3 study enrollment. | Enrollment / accrual |
| NCT02082405 | Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple… | Phase 2 | withdrawn | Mar 10, 2014 | Case Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT00092274 | Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma | Phase 1 / Phase 2 | withdrawn | Sep 27, 2004 | GlaxoSmithKline | Acquired asset | Other (stated, no rule matched) |
| NCT00319332 | A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab… | Phase 3 | withdrawn | Apr 27, 2006 | GlaxoSmithKline | This study has been cancelled prior to enrollment | Enrollment / accrual |
| NCT00503763 | Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma(PSMMSS) | Phase 2 | withdrawn | Jul 19, 2007 | Meir Medical Center | We found out that there is another study on the same issue | Other (stated, no rule matched) |
| NCT00242528 | Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients… | Phase 4 | withdrawn | Oct 20, 2005 | Novartis | not stated | Not stated |
| NCT00706953 | A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed… | Phase 2 | withdrawn | Jun 30, 2008 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | not stated | Not stated |
| NCT01062230 | Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma | Phase 2 | terminated | Feb 4, 2010 | University of Arkansas | Slow accrual; PI left primary institution | Investigator |
| NCT00210392 | VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy | Phase 2 | terminated | Sep 21, 2005 | International Extranodal Lymphoma Study Group (IELSG) | After IELSG25A study amendment, patients subject of the present study were eligible for inclusion… | Other (stated, no rule matched) |
| NCT00748631 | Treatment of Malignant Vertebral Fractures With Percutaneous Balloon Kyphoplasty.(KYPHOK) | N/A | terminated | Sep 8, 2008 | Assistance Publique - Hôpitaux de Paris | the data collected are enough to obtain a qualitative analysis. | Other (stated, no rule matched) |
| NCT02353468 | Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma… | Phase 2 | terminated | Feb 2, 2015 | University of Colorado, Denver | Principle investigator left the institution | Investigator |
| NCT02353572 | Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients… | Phase 1 / Phase 2 | terminated | Feb 2, 2015 | University of Colorado, Denver | Principle investigator left the institution | Investigator |
| NCT00005834 | S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory… | Phase 3 | terminated | Mar 16, 2004 | SWOG Cancer Research Network | poor accrual | Enrollment / accrual |
| NCT01055301 | S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous… | Phase 2 | withdrawn | Jan 25, 2010 | SWOG Cancer Research Network | lack of accrual | Enrollment / accrual |
| NCT00516191 | A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in…(DMV) | Phase 1 / Phase 2 | withdrawn | Aug 15, 2007 | University of California, San Francisco | low accrual | Enrollment / accrual |
| NCT00891033 | Panobinostat/Velcade in Multiple Myeloma | Phase 1 | terminated | Apr 30, 2009 | University of Arkansas | This study was terminated because the drug company stopped making the study drug | Sponsor / business decision |
| NCT01449539 | Study of Hyperbaric Oxygen Therapy in Addition to Standard Growth Factor Support for… | N/A | terminated | Oct 10, 2011 | University of Arkansas | Study was terminated early because the site that administered the hyperbaric oxygen treatment… | Other (stated, no rule matched) |
| NCT01302366 | A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma | Phase 2 | terminated | Feb 24, 2011 | NYU Langone Health | due to lack of funding | Funding |
| NCT01537861 | Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory… | Early Phase 1 | terminated | Feb 23, 2012 | Washington University School of Medicine | Unexpected toxicity (2 early deaths) | Safety / toxicity |
| NCT00060671 | Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's… | Phase 3 | terminated | May 12, 2003 | CTI BioPharma | not stated | Not stated |
| NCT00719901 | Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | terminated | Jul 22, 2008 | National Cancer Institute (NCI) | This trial was terminated due to slow accrual and the drug supply of Obatoclax during the phase I;… | Drug supply |
| NCT01078441 | Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in… | Phase 2 | terminated | Mar 2, 2010 | National Cancer Institute (NCI) | The study was closed early due to weak accrual on June 26, 2012. | Enrollment / accrual |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or… | Phase 1 | terminated | Mar 17, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01653418 | Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell…(V-BEAM) | Phase 2 | terminated | Jul 31, 2012 | Washington University School of Medicine | Due to the high rate of morbidity and mortality | Other (stated, no rule matched) |
| NCT00288067 | Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | terminated | Feb 7, 2006 | National Cancer Institute (NCI) | NCI stopped supplying fenretinide in November of 2012. | Other (stated, no rule matched) |
| NCT00594308 | In-Vivo Activated T-Cell Depletion to Prevent GVHD | N/A | terminated | Jan 15, 2008 | Indiana University | Treatment ineffective | Other (stated, no rule matched) |
| NCT00675428 | Study of Natalizumab in Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | terminated | May 9, 2008 | Biogen | Sponsor decision due to low enrollment and not safety concerns. | Safety / toxicity |
| NCT00240162 | PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma | Phase 2 | terminated | Oct 17, 2005 | Washington University School of Medicine | investigator letter from drug manufacturer stating animal studies showed increased risk of cancer… | Safety / toxicity |
| NCT02115035 | A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of… | Phase 1 / Phase 2 | withdrawn | Apr 15, 2014 | University of Arkansas | Funding issues | Funding |
| NCT01914718 | Dose-adjusted EPOCH-R in MYC Positive DLBCL | Phase 2 | terminated | Aug 2, 2013 | Fudan University | Poor accrual of eligible patients | Enrollment / accrual |
| NCT01005979 | A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of… | Phase 1 | terminated | Nov 2, 2009 | Emory University | Slow Accrual | Enrollment / accrual |
| NCT01301963 | Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma… | Phase 3 | terminated | Feb 23, 2011 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT01397591 | Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell,… | Phase 2 | terminated | Jul 19, 2011 | OHSU Knight Cancer Institute | Study closed by PI due to lower than expected accrual. | Enrollment / accrual |
| NCT01534949 | Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to…(Triad-DLBCL) | Phase 1 | terminated | Feb 17, 2012 | Celltrion | not stated | Not stated |
| NCT02114502 | Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous… | Phase 2 | withdrawn | Apr 15, 2014 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT01466868 | Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma(AKTIL) | Phase 2 | terminated | Nov 8, 2011 | Centre Leon Berard | Regarding the comments of the iDSMB, the sponsor decided to stop the inclusions | Sponsor / business decision |
| NCT02079519 | A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma | Phase 2 | terminated | Mar 5, 2014 | Hoffmann-La Roche | The study was discontinued prematurely by the sponsor due to a lack of recruitment. | Enrollment / accrual |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | Phase 1 / Phase 2 | terminated | Aug 5, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00387426 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | Phase 2 | terminated | Oct 13, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00872300 | PHA-739358 for the Treatment of Multiple Myeloma | Phase 2 | terminated | Mar 31, 2009 | Nerviano Medical Sciences | Low recruitment rate | Enrollment / accrual |
| NCT00100711 | Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or… | Phase 2 | terminated | Jan 5, 2005 | Pharmacyclics LLC. | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 7, 2015source: clinicaltrials